BOVINE RESPIRATORY SYNCYTIAL VIRUS AS A HUMAN VACCINE

尽管经过了30年的努力，目前还没有获得许可的疫苗 对抗呼吸道合胞病毒(RSV)，最重要的原因是 全世界的婴儿肺部疾病。牛呼吸道合胞病毒 (BRSV)与RSV在抗原性上相关，在 实验动物，并对RSV提供了非常显著的保护 在血清阴性动物中的感染。它似乎不会导致强化 疾病，与以前的候选疫苗不同。因为几乎所有的 RSV疫苗的潜在接受者将是患有 大量的母源性RSV抗体，而且因为 这种抗体已被证明可以阻断其他候选抗体的疗效 疫苗，这项建议的具体目的是测试有效性和 人呼吸道合胞病毒抗体对棉鼠BRSV的安全性 其数量相当于人类婴儿的数量。如果BRSV保护 在这些条件下，针对RSV的后续研究将包括 临床试验。

Despite efforts spanning three decades, there is no licensed vaccine against respiratory syncytial virus (RSV), the most important cause of infant pulmonary disease worldwide. Bovine respiratory syncytial virus (BRSV) is antigenically related to RSV, causes no significant pathology in laboratory animals, and confers highly significant protection against RSV infection in seronegative animals. It appears not to cause potentiated disease, unlike previous candidate vaccines. Because virtually all potential recipients of an RSV vaccine would be infants possessing substantial amounts of maternally derived antibody to RSV, and because such antibody has been shown to block the efficacy of other candidate vaccines, the specific aim of this proposal is to test the efficacy and safety of BRSV in cotton rats previously administered human RSV antibody in amounts equivalent to those seen in human infants. If BRSV protects against RSV under these conditions, followup studies would include clinical trials.